3rd Quarter Results (6206W)
23 November 2010 - 8:00AM
UK Regulatory
TIDMMDST
RNS Number : 6206W
Medicsight Plc
23 November 2010
Press Release 23 November 2010
Medicsight PLC
("Medicsight" or "the Group")
Third Quarter Summary Trading Statement
Medicsight PLC (AIM: MDST), industry leader in the development
of Computer-Aided Detection (CAD) and image analysis software to
assist in the early detection and diagnosis of disease, is pleased
to announce its results for the nine months ended 30 September
2010.
Highlights
-- Revenue increased to GBP253,000 (30 September 2009:
GBP94,000) with significant contribution from the
MedicCO2LON insufflator in Q2
-- Operating costs reduced to GBP3,772,000 (30 September
2009: GBP6,720,000)
-- Operating loss before interest and tax of GBP3,594,000
(30 September 2009: GBP6,626,000)
-- Group cash balance at 30 September 2010 of GBP6,415,000
(31 December 2009: GBP10,708,000)
-- Total assets position at 30 September 2010 was GBP7,511,000
(31 December 2009: GBP11,120,000)
-- Granted SFDA approval in China for ColonCAD 4.0 on
13 October 2010
-- Responded to the US Food & Drug Administration's
(FDA) second Additional Information request letter
on 2 June 2010
-- Signed global distribution agreement for the new
MedicCO2LON insufflator product with MEDRAD Inc on
13 January 2010
Allan Rowley, Chief Executive of Medicsight PLC, commented:
"During the nine months ended 30 September 2010 we recorded
GBP253,000 of revenue (2009: GBP94,000), of which GBP113,000 (2009:
GBP94,000) was for ColonCAD and GBP140,000 (2009: nil) was for our
MedicCO2LON Insufflator product that we launched in Q1 of this
year.
"We maintain a tight control of operating costs, which were
GBP3,772,000 for the nine months ended 30 September 2010, compared
to GBP6,720,000 for the previous year. This year on year reduction
is due to our 2009 cost reduction program.
"On regulatory approvals, we responded to the FDA's second
Additional Information (AI) request on 2 June 2010. We are in
regular dialogue and continue to work closely with our FDA review
team. We are also working closely with our reviewers at the
Japanese Ministry of Health, Labour and Welfare (MHLW).
"We remain in a strong cash position with a cash balance of
GBP6,415,000 at 30 September 2010."
- ENDS -
For further information:
Medicsight plc
Allan Rowley, CEO Tel: +44 (0)207 605 7950
www.medicsight.com
Daniel Stewart & Co
Emma Earl / Oliver Rigby Tel: +44 (0) 207 776
6550
www.danielstewart.co.uk
Media enquiries:
Abchurch Communications
www.abchurch-group.com
Heather Salmond Tel: +44 (0) 207 398
7704
heather.salmond@abchurch-group.com
Simone Elviss Tel: +44 (0) 207 398
7728
simone.elviss@abchurch-group.com
Quincy Allan Tel: +44 (0) 207 398
7710
quincy.allan@abchurch-group.com
Notes to editors
Medicsight plc is a UK-headquartered, research driven, leading
developer of computer-aided detection (CAD) and image analysis
software for the medical imaging market. The CAD software
automatically highlights suspicious areas on computerised
tomography (CT) scans of the colon and lung, helping radiologists
to identify, measure and analyse potential disease and early
indicators of disease. Medicsight's CAD software has been developed
using one of the world's largest and most population diverse
databases of verified patient CT scan data. Medicsight's
ColonCAD(TM) and LungCAD(TM) software products are seamlessly
integrated with the advanced 3D visualisation workstations of
several industry-leading imaging equipment partners.
About Computer-Aided Detection
With increasingly sophisticated radiological imaging hardware
such as Multi-Detector CT scanners, radiologists are facing a
growing challenge in the amount of detailed patient image data that
they must review for each patient examination. Some CT scan
examinations generate as many as 2000 images per patient. Review of
this data by the radiologist is not only time-consuming but also
prone to error due to reader fatigue. CAD software can help the
reviewing radiologist by analysing the image data and automatically
highlighting suspicious regions of interest for closer inspection.
Without CAD software some potential abnormalities or areas of
disease may be overlooked. This can be critical for diagnosis and
the management of patient outcomes as early detection of disease
greatly increases the probability of successful treatment and a
positive therapeutic outcome. In addition to supporting individual
radiologists CAD also has the potential to help standardise CT
interpretation across both individuals and institutions thereby
supporting population based screening programmes.
About Medicsight's CAD software
Medicsight's ColonCAD(TM) and LungCAD(TM) software use an
advanced CAD algorithm to analyse CT scans of the colon and lung
and automatically highlight suspicious areas that may be indicators
of disease. CAD may highlight areas easily overlooked by the
reviewing radiologist, such as small lesions or regions that are
hidden from view behind folds in the colon or normal structures and
surrounding tissue in the lung.
Both CAD products seamlessly integrate with the advanced 3D
visualisation platforms of industry-leading imaging equipment
partners. The integrated systems provide sophisticated image
viewing capabilities, including 3D reconstructed image data, with
the added advantage of demonstrating automatic CAD findings to
assist clinical end users in the detection and analysis of disease.
This allows clinical end users to perform either a 'second read',
where CAD findings are displayed to the user after completion of an
initial review of the CT scan data, or a 'concurrent read' where
CAD findings are displayed during the user's initial review of the
original CT scan images.
Since inception, Medicsight has developed close and lasting
relationships with some of the world's foremost clinicians in
product related areas. This provides the Company with a wealth of
clinical expertise and dedicated clinical research to support
ongoing product development. Medicsight also collaborates with a
number of leading academic institutions and clinical research
programmes worldwide to develop the Company's comprehensive
database of population diverse verified patient CT scan data, thus
allowing Medicsight's products to be validated to the highest
possible standards.
This information is provided by RNS
The company news service from the London Stock Exchange
END
QRTFEAFWEFSSEFF
Medicsight (LSE:MDST)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Medicsight (LSE:MDST)
Historical Stock Chart
Von Dez 2023 bis Dez 2024